EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
The Ambitious Pipeline of EpiCept Corporation
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
